Akash Tewari
Stock Analyst at Jefferies
(2.45)
# 2,436
Out of 5,141 analysts
61
Total ratings
39.13%
Success rate
4.7%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Buy | $28 → $35 | $39.23 | -10.78% | 2 | Nov 3, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $83 → $96 | $83.15 | +15.45% | 2 | Sep 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $813 → $831 | $779.67 | +6.58% | 5 | Aug 27, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $26 | $11.60 | +124.14% | 1 | Aug 25, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $11.99 | -16.60% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $60.66 | +12.10% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $64.08 | +48.25% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $110.15 | +36.18% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $8.70 | +83.91% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $128.63 | +46.93% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $22.28 | +259.07% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $994 → $1,015 | $1,009.52 | +0.54% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $31.91 | +56.69% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $68.39 | +9.67% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $43.21 | -28.26% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $26.65 | +46.34% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $13.51 | +33.23% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $844.41 | -39.25% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $122.26 | +2.24% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $22.72 | -51.58% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.53 | +1,011.11% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $67.94 | +10.39% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $435.01 | -65.29% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $43.63 | -35.82% | 3 | Oct 7, 2021 |
Terns Pharmaceuticals
Nov 3, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $39.23
Upside: -10.78%
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $83 → $96
Current: $83.15
Upside: +15.45%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Buy
Price Target: $813 → $831
Current: $779.67
Upside: +6.58%
Crescent Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $26
Current: $11.60
Upside: +124.14%
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $11.99
Upside: -16.60%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $60.66
Upside: +12.10%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $64.08
Upside: +48.25%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $110.15
Upside: +36.18%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $8.70
Upside: +83.91%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $128.63
Upside: +46.93%
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $22.28
Upside: +259.07%
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $1,009.52
Upside: +0.54%
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $31.91
Upside: +56.69%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $68.39
Upside: +9.67%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $43.21
Upside: -28.26%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $26.65
Upside: +46.34%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $13.51
Upside: +33.23%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $844.41
Upside: -39.25%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $122.26
Upside: +2.24%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $22.72
Upside: -51.58%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.53
Upside: +1,011.11%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $67.94
Upside: +10.39%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $435.01
Upside: -65.29%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $43.63
Upside: -35.82%